Dr. Berra Yazar-Klosinski
Founder and CEO of Yazar Lab, LLC
Dr. Berra Yazar-Klosinski is an internationally recognized scientist and executive advancing psychedelic medicine. She is Founder and CEO of Yazar Lab, LLC, Chief Development Officer of Freedom Biosciences, and former Chief Scientific Officer at Lykos Therapeutics and MAPS.
Her work has been instrumental in the clinical development and regulatory advancement of psychedelic therapies, particularly MDMA-assisted therapy for post-traumatic stress disorder (PTSD). She led pivotal Phase 3 clinical trials and guided multidisciplinary teams through regulatory strategy, the first psychedelic New Drug Application (NDA) submission, and regulatory inspections by the FDA and Health Canada.
Her research spans MDMA, psilocybin, LSD, cannabis, and ibogaine, with a focus on therapeutic outcomes, safety, biomarkers, and mechanisms of action. As a Turkish American, she champions diversity, equity, and inclusion, advocating for rigorous, patient-centered research and culturally informed access to emerging mental health treatments.